Hinden L, et al. - The contributors intended to identify the immune, hematological, and biochemical parameters that characterize the population of graft vs host disease (GvHD) patients responding to mesenchymal stromal cells (MSC) therapy, relative to non-responding patients. A good response to therapy could be predicted via the level of lymphocytes, in particular T and NK cells. A better response among patients who expressed low levels of IL-6 and IL-22, Th17 related cytokines, prior to therapy was observed. A poorer response was shown in high levels of bilirubin in patients prior to therapy. Hence, it was concluded the facilitation of early prediction of success or failure of the treatment and also, improvement in selection of patients for MSC therapy.